Chronic hepatitis B
Conditions
Interventions
low-level viremia group:Chronic hepatitis B patients who meet the criteria of hypoviremia are divided into three groups on a voluntary basis, one group: nucleoside analogues combined with technical dr
Group 2: Nucleoside analogues combined with dressing changes and polyethylene glycol interferon a- 2b (Pegbin)
Group 3: Nucleoside analogues combined with dressing change single us
Complete virology response group:CHB patients with complete virology response were divided into two groups on a voluntary basis, one group: NUCs technical drug+PegIFN a- 2b
Group 2: NUCs technical single use
Sponsors
Shengjing Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of chronic hepatitis B 2. Age range from 18 to 60 years old, regardless of gender; 3. Patients who have been receiving NAs treatment for more than 1 year 4.TBil<2ULN 5. No contraindications to interferon treatment and willing to accept Peg-IFN a- 2b treatment, sign the informed consent form for interferon treatmen
Exclusion criteria
Exclusion criteria: 1. Patients with combined HAV, HCV, HDV, HEV infections, and autoimmune liver disease; 2. Pregnant and lactating women, as well as patients who are preparing to give birth recently; 3. Patients with liver cirrhosis 4. Have a history of serious heart disease, including unstable or uncontrolled heart disease within 6 months; 5. Have a history of mental illness; 6. Uncontrolled epilepsy; 7. Drunken or drug users who have not quit; 8. Uncontrolled diabetes, hypertension, thyroid disease, retinopathy, autoimmune disease, etc; 9. Total bilirubin>34umol/L; 10. Determine patients with past or current liver cirrhosis or liver cancer through liver ultrasound or liver hardness measurement; 11. Neutrophil count<2 × 109/L and/or platelet count<100 × 109 /L? 12. Other situations that the supervising physician deems unsuitable for enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA;HBsAg; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBeAg;HBeAb;HBV RNA; | — |
Countries
China
Contacts
Public ContactZhiwei Li
Shengjing Hospital of China Medical University
Outcome results
None listed